Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-COMP-14 as front-line therapy for Waldenstrom macroglobulinemia
2013-002388-25Phase 2Terminated
- Sponsor
- Ospedali Riuniti Marche Nord
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone in Waldenström macroglobulinemia (WM), sponsored by Ospedali Riuniti Marche Nord. Primary endpoint: 1-year complete remission rate. Started Jan 2014; status: terminated.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2013-002388-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002388-25.